Datavant vs Bristol Myers Squibb
Side-by-side comparison of AI visibility scores, market position, and capabilities
Datavant is the largest health data ecosystem connecting healthcare organizations through privacy-preserving tokenization that enables real-world data linkage across systems.
About
Datavant is a health data company founded in 2017 that has built the largest real-world health data ecosystem in the United States through its privacy-preserving data tokenization technology. The company's platform enables healthcare organizations including hospitals, insurers, pharmaceutical companies, and research institutions to link patient records across databases without sharing identifying information, using consistent de-identified tokens that allow data to be joined securely. Datavant raised over $600M and expanded significantly through its merger with Ciox Health, combining Datavant's tokenization technology with Ciox's medical record retrieval operations. The company serves life sciences companies that need real-world evidence from claims, EHR, and specialty data sources, payers managing population health programs, and health systems that want to generate revenue from their patient data while maintaining privacy compliance. Datavant's network effect grows as more organizations adopt the tokenization standard, making the ecosystem more valuable for every participant. The platform has become critical infrastructure for real-world evidence generation in pharmaceutical development and health economics research.
Princeton NJ biopharma (NYSE: BMY) at $48.3B 2024 revenue; Eliquis $13.3B, Opdivo $9.2B, Cobenfy schizophrenia launch; $23B acquisitions (Karuna+Mirati+RayzeBio) building next pipeline vs. Pfizer and Merck.
About
Bristol Myers Squibb (BMS) is a Princeton, New Jersey-based global biopharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: BMY) as an S&P 500 Healthcare component — discovering, developing, and delivering innovative medicines for serious diseases including cancer, cardiovascular disease, immunology, and neuroscience through approximately 34,000 employees worldwide. In fiscal year 2024, BMS reported total revenue of $48.3 billion (+7% year-over-year), with its Growth Portfolio generating $22.6 billion (+17%), driven by blockbusters Eliquis ($13.3B anticoagulant), Opdivo ($9.2B immuno-oncology), and Revlimid ($5.8B multiple myeloma). New product revenue surged 77% to $3.6 billion, led by schizophrenia treatment Cobenfy (formerly KarXT), CAR-T therapy Breyanzi, anemia drug Reblozyl, and Opdualag checkpoint inhibitor combination. CEO Dr. Christopher Boerner assumed leadership in November 2023, accelerating BMS's pipeline expansion through three transformative acquisitions in 2024: Karuna Therapeutics ($14B, Cobenfy/KarXT for schizophrenia and Alzheimer's agitation), Mirati Therapeutics ($4.8B, KRAS-targeted oncology), and RayzeBio ($4.1B, radiopharmaceutical cancer therapy).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.